Printer Friendly

STRATEGIC RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE IN THE AREA OF CARDIOVASCULAR DISEASES

 STRATEGIC RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE IN THE AREA OF CARDIOVASCULAR DISEASES
 LAVAL, Quebec, April 3 /PRNewswire/ -- BioChem Pharma Inc. (NASDAQ: BCHXF; Montreal, Toronto: BCH) and the Biotechnology Research Institute of the National Research Council of Canada have entered into a strategic research collaboration in the area of cardiovascular diseases, BioChem announced today.
 The agreement in principle calls for BioChem and BRI to conduct a three-year collaborative research program at their respective facilities. The contribution of both parties in the joint program will amount to some $6 million. BioChem will contribute in part to the funding of the BRI research and will acquire exclusive worldwide commercial rights to discoveries resulting from the research program.
 The focus of the research effort is twofold. BRI has already discovered a compound P-79 that has shown potent and long-acting anti- thrombotic effects in laboratory tests. In continuance of the program, BRI and BioChem will accelerate the research of a new generation of anti-thrombotic compounds with potential application for the treatment of cardiovascular diseases. BioChem will contribute to the research program its medicinal chemistry expertise, particularly in the area of synthetic peptide technology, and will be responsible for development and eventual commercialization.
 The Biotechnology Research Institute's contribution to the research program is in the areas of protein engineering and biomolecular modelling where it has an expertise of international reputation.
 Francesco Bellini, president and chief executive officer of BioChem Pharma, said, "The agreement represents an important milestone in the search to cure cardiovascular diseases, including heart attacks and strokes caused by thrombosis, which are significant causes of morbidity and mortality, especially in the Western World.
 "This agreement will allow us to break new ground in therapeutic research by combining BioChem's expertise in drug development and NRC-BRI's state-of-the-art capabilities in biotechnology," Bellini said.
 Maurice Brossard, vice president of biotechnology at the National Research Council and director general of the Biotechnology Research Institute in Montreal, indicated that "the agreement represents a very clear example of the role and mission of the Institute to support the development of the biotechnology industry through oriented generic research at the international level. BRI is pleased that this broad knowledge in protein engineering which has given rise to the P-79 compound is being transferred to BioChem Pharma Inc."
 BioChem Pharma Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases.
 The Biotechnology Research Institute of the National Research Council is the largest biotechnology research institute in Canada dedicated to the development of generic R&D and know-how in support of industrial development. Its research programs are in the areas of bio-engineering and molecular biology. It also has a major pilot plant facility for large scale up production of bio-pharmaceutical products. It is located in Montreal.
 -0- 4/3/92
 /CONTACT: Thomas Babinski of BioChem, 514-681-1744, or after hours, 514-344-9958; Maurice Brossard, director general of BRI, 514-496-6101; or Michele Roy or Luc Beauregard of NATIONAL Public Relations, 514-843-7171, for BioChem/
 (BCHXF) CO: BioChem Pharma Inc.; Biotechnology Research Institute ST: Quebec IN: MTC SU:


GK-TS -- NY021 -- 4770 04/03/92 10:28 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 3, 1992
Words:527
Previous Article:DELAWARE CHANCERY COURT ENTERS FINAL JUDGMENT ON REMOVAL OF PARRETTI DIRECTORS OF PCC
Next Article:LIZ CLAIBORNE ANNOUNCES INCREASE IN CASH DIVIDEND
Topics:


Related Articles
IAF BIOCHEM INTERNATIONAL BECOMES BIOCHEM PHARMA
BIOCHEM AND ASTRA REACH AGREEMENT ON PAIN CONTROL COMPOUNDS
AGREEMENT SIGNED FOR RESEARCH COLLABORATION BETWEEN BIOCHEM PHARMA AND THE BIOTECHNOLOGY RESEARCH INSTITUTE OF NRC
PAIN CONTROL: BIOCHEM AND ASTRA AGREEMENT SIGNED TODAY
LAMIVUDINE: EARLY PHASE II TRIAL RESULTS ENCOURAGING; LATE PHASE II TRIALS INITIATED
BIOCHEM PHARMA PURCHASES AN EQUITY STAKE IN ANTISOMA
ZEFFIX, FOR TREATMENT OF CHRONIC HEPATITIS B, APPROVED IN THE EUROPEAN UNION.
Microbiotix and BioChem Pharma Enter Into Collaboration to Develop Novel Antibiotic Agents.
Biochem Pharma Announces Development Collaboration and Licensing Agreement With Cytovax Biotechnologies@.
Biochem Pharma Sells its Stake in North American Vaccine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters